TGIF2 and hepatocellular carcinoma: We believe that miR-34a blocks osteoporosis and BM by inhibiting osteoclastogenesis in HCC patients because miR-34a has been found to directly target transforming growth factor-β-induced factor 2 (TGIF2) and to reduce bone resorption [24].